Novartis AG

The current price of NVS is $164.49 — it has increased by 3.28% since the previous close. Data as of Nov 4, 2026.

NVS is up 1.21% over the past week, up 16.66% over the past month and up 31.58% over the past year. The price is above its 200-day moving average of $151.97.

Analysts' average 12-month price target for NVS is $149.50, which implies 9.11% downside from the current price. Individual estimates range from $136.00 to $163.00.

Of the 11 analysts covering Novartis AG, 3 rate it a strong buy, 2 rate it a buy, 4 rate it a hold, 1 rates it a sell and 1 rates it a strong sell. The overall consensus is neutral. Analyst ratings are opinions and do not guarantee future performance.

Novartis AG has a market capitalization of $310.66B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Novartis AG posted earnings of $2.46 per share against an estimate of $2.25, beating expectations by 9.33%. Upcoming reports are listed in the earnings calendar.

Novartis AG reported revenue of $14.52B in its most recent quarter, which has increased by 1.14% compared with the same quarter a year earlier. Analysts had expected $14.53B.

Yes. Novartis AG pays dividends annually. The latest payment of $4.74 per share has a payment date of Mar 16, 2026, which corresponds to a dividend yield of 3.04%.

Companies most comparable to Novartis AG include Johnson & Johnson, AbbVie Inc., Merck & Co., Inc., AstraZeneca PLC and Gilead Sciences, Inc.

In the latest trading session NVS moved between $162.16 and $164.74, a range of 1.57% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Novartis AG shows a strong buy rating today. Technical ratings are indicators, not investment advice.

Over the past 52 weeks NVS has traded between $123.24 and $170.46. The current price is 3.50% below its 52-week high.